-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Celldex Therapeutics, Lowers Price Target to $60

Benzinga·07/22/2026 11:17:25
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $62 to $60.